BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36012136)

  • 1. Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database.
    Mine K; Kawashiri T; Inoue M; Kobayashi D; Mori K; Hiromoto S; Kudamatsu H; Uchida M; Egashira N; Koyanagi S; Ohdo S; Shimazoe T
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethyl Fumarate Attenuates Oxaliplatin-Induced Peripheral Neuropathy without Affecting the Anti-tumor Activity of Oxaliplatin in Rodents.
    Miyagi A; Kawashiri T; Shimizu S; Shigematsu N; Kobayashi D; Shimazoe T
    Biol Pharm Bull; 2019; 42(4):638-644. PubMed ID: 30930422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro.
    Shigematsu N; Kawashiri T; Kobayashi D; Shimizu S; Mine K; Hiromoto S; Uchida M; Egashira N; Shimazoe T
    Sci Rep; 2020 Apr; 10(1):6734. PubMed ID: 32317735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases.
    Kobayashi A; Ikemura K; Wakai E; Kondo M; Okuda M
    Anticancer Res; 2023 Dec; 43(12):5613-5620. PubMed ID: 38030205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect.
    Kawashiri T; Shimizu S; Shigematsu N; Kobayashi D; Shimazoe T
    J Pharmacol Sci; 2019 Jul; 140(3):291-294. PubMed ID: 31377017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi.
    Mizuno K; Shibata K; Komatsu R; Omiya Y; Kase Y; Koizumi S
    Cancer Biol Ther; 2016 Nov; 17(11):1206-1212. PubMed ID: 27416484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
    Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
    Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.
    Zamami Y; Niimura T; Kawashiri T; Goda M; Naito Y; Fukushima K; Ushio S; Aizawa F; Hamano H; Okada N; Yagi K; Miyata K; Takechi K; Chuma M; Koyama T; Kobayashi D; Shimazoe T; Fujino H; Izawa-Ishizawa Y; Ishizawa K
    Biomed Pharmacother; 2022 Apr; 148():112744. PubMed ID: 35240525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of Cystine and Theanine ameliorates oxaliplatin-induced chronic peripheral neuropathy in rodents.
    Kawashiri T; Kobayashi D; Egashira N; Tsuchiya T; Shimazoe T
    Sci Rep; 2020 Jul; 10(1):12665. PubMed ID: 32728157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents.
    Ushio S; Egashira N; Sada H; Kawashiri T; Shirahama M; Masuguchi K; Oishi R
    Eur J Cancer; 2012 Jun; 48(9):1407-13. PubMed ID: 21907570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
    Kang L; Tian Y; Xu S; Chen H
    J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy.
    Areti A; Komirishetty P; Kalvala AK; Nellaiappan K; Kumar A
    Mol Neurobiol; 2018 Sep; 55(9):7463-7475. PubMed ID: 29427084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats.
    Fujita S; Ushio S; Ozawa N; Masuguchi K; Kawashiri T; Oishi R; Egashira N
    PLoS One; 2015; 10(11):e0141921. PubMed ID: 26536615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-Angiotensin-Aldosterone System Inhibitors Prevent the Onset of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Multicenter Study and in Vitro Evaluation.
    Uchida M; Ushio S; Niimura T; Takechi K; Kawazoe H; Hidaka N; Tanaka A; Araki H; Zamami Y; Ishizawa K; Kitamura Y; Sendou T; Kawasaki H; Namba H; Shibata K; Tanaka M; Takatori S
    Biol Pharm Bull; 2022 Feb; 45(2):226-234. PubMed ID: 34803077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence.
    Kawashiri T; Mine K; Kobayashi D; Inoue M; Ushio S; Uchida M; Egashira N; Shimazoe T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
    Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
    ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidants Improve Oxaliplatin-Induced Peripheral Neuropathy in Tumor-Bearing Mice Model: Role of Spinal Cord Oxidative Stress and Inflammation.
    Agnes JP; Santos VWD; das Neves RN; Gonçalves RM; Delgobo M; Girardi CS; Lückemeyer DD; Ferreira MA; Macedo-Júnior SJ; Lopes SC; Spiller F; Gelain DP; Moreira JCF; Prediger RD; Ferreira J; Zanotto-Filho A
    J Pain; 2021 Aug; 22(8):996-1013. PubMed ID: 33774154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice.
    Ogihara T; Nakagawa T; Hayashi M; Koyanagi M; Yonezawa A; Omura T; Nakagawa S; Kitada N; Imai S; Matsubara K
    J Pharmacol Sci; 2019 Dec; 141(4):131-138. PubMed ID: 31734027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
    Minami T; Takeda M; Sata M; Kato H; Yano K; Sakai T; Tsujita R; Kawasaki K; Ito A
    Eur J Pharmacol; 2020 Aug; 880():173196. PubMed ID: 32416186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.